Comparison of rapid screening immunoassay and intradermal test for canine atopic dermatitis

2015 ◽  
Vol 16 (3) ◽  
pp. 115-120
Author(s):  
Yeseul Lee ◽  
Ji-Houn Kang ◽  
Dong-In Jung ◽  
Young-Bae Jin ◽  
Sang-Rae Lee ◽  
...  
2018 ◽  
Vol 49 (1) ◽  
pp. 16
Author(s):  
M. N. SARIDOMICHELAKIS (Μ. Ν. ΣΑΡΙΔΟΜΙΧΕΛΑΚΗΣ) ◽  
A. F. KOUTINAS (Α.Φ. ΚΟΥΤΙΝΑΣ)

Canine atopic dermatitis is a common clinical entity, characterized by pruritus due to sensitization against common enviromental allergens. It has been proven that there is strong breed predisposition. Genetically programmed dogs overproduct reaginic antibodies (IgE and/or IgGd) after their exposure to airborne allergens (dust mites, epithelia, pollens and molds) which consequently fix themselves to the mast cells of the skin. After reexposure to the same allergens these cells degranulate, with subsequent release of many pharmacologically active substances (histamine, leucotrienes, Prostaglandines etc). However, this is a rather simplistic explanation; the true pathogenesis of atopy is more complicated and still not well understood. Clinical signs first appear between 6 months and 3 years of age. Pruritus, the mainstay of atopy, can be seasonal or perennial. Skin lesions, appearing in later, are attributed to pruritus and/or to secondary complications (staphylococcal pyoderma, seborrhea, dry skin, Malassezia dermatitis). The diagnosis, based on history and clinical findings, necessitates exclusion of other pruritic skin diseases and identification of the offending allergens by using the intradermal test and/or serology (ELISA, RAST). The latter method is diagnostically inferior to intradermal skin test due to the high rate of false positive reactions. Therapeutic options include avoidance of the allergens responsible for sensitization, systemic therapy with glucocorticoids, antihistamines and essential fatty acids in various combinations, topical antipruritic therapy, hyposensitization which is the best therapeutical modality for the perennial form of the disease and management of secondary complications as well as of other concurrent allergic skin diseases, such as food and flea allergy.


2019 ◽  
Vol 143 (2) ◽  
pp. AB67
Author(s):  
Ichiro Imanishi ◽  
Jumpei Uchiyama ◽  
Takako Matsuda ◽  
Keijiro Mizukami ◽  
Hidekatsu Shimakura ◽  
...  

2021 ◽  
Vol 136 ◽  
pp. 74-80
Author(s):  
Sayaka Shiomitsu ◽  
James Gillen ◽  
Salvatore Frasca ◽  
Domenico Santoro

2013 ◽  
Vol 24 (1) ◽  
pp. 54-e14 ◽  
Author(s):  
Jolanta Klukowska-Rötzler ◽  
Ludovic Chervet ◽  
Eliane J. Müller ◽  
Petra Roosje ◽  
Eliane Marti ◽  
...  

2017 ◽  
Vol 181 (5) ◽  
pp. 118-118 ◽  
Author(s):  
I. Wagner ◽  
K. J. Geh ◽  
M. Hubert ◽  
G. Winter ◽  
K. Weber ◽  
...  

Cytosine-phosphate-guanine oligodeoxynucleotides (CpG ODN) are a promising new immunotherapeutic treatment option for canine atopic dermatitis (AD). The aim of this uncontrolled pilot study was to evaluate clinical and immunological effects of gelatine nanoparticle (GNP)-bound CpG ODN (CpG GNP) on atopic dogs. Eighteen dogs with AD were treated for 8 weeks (group 1, n=8) or 18 weeks (group 2, n=10). Before inclusion and after 2 weeks, 4 weeks, 6 weeks (group 1+2), 8 weeks, 12 weeks and 16 weeks (group 2) 75 µg CpG ODN/dog (bound to 1.5 mg GNP) were injected subcutaneously. Pruritus was evaluated daily by the owner. Lesions were evaluated and serum concentrations and mRNA expressions of interferon-γ, tumour necrosis factor-α, transforming growth factor-β, interleukin (IL) 10 and IL-4 (only mRNA expression) were determined at inclusion and after 8 weeks (group 1+2) and 18 weeks (group 2). Lesions and pruritus improved significantly from baseline to week 8. Mean improvements from baseline to week 18 were 23 per cent and 44 per cent for lesions and pruritus, respectively, an improvement of ≥50 per cent was seen in six out of nine and three out of six dogs, respectively. IL-4 mRNA expression decreased significantly. The results of this study show a clinical improvement of canine AD with CpG GNP comparable to allergen immunotherapy. Controlled studies are needed to confirm these findings.


Sign in / Sign up

Export Citation Format

Share Document